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Recent work has shown that the AML1/ETO fusion pro-
tein acts as a dominant negative inhibitor of normal Aml1
function (Yergeau et al., 1997) and also up-regulates the
expression of the bcl-2 protooncogene (Klampfer et al.,
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Bcl-2 was discovered upon characterization of aStanford, California 94305
t(14;18) chromosomal translocation found in follicular
lymphoma (Bakhshi et al., 1985; Cleary and Sklar, 1985)
and was subsequently shown to protect cells from aSummary
wide variety of apoptotic cues (Vaux et al., 1988; re-
viewed in Yang and Korsmeyer, 1996). The role of Bcl-2Fas-deficient (Faslpr/lpr) mice constitutively expressing
in oncogenesis has been confirmed mainly in lymphoidBcl-2 in myeloid cells by the hMRP8 promoter often
cells, but recent work has suggested that deregulationdevelop a fatal disease analogous to human acute
of the bcl-2 gene may be important in the transformationmyeloblastic leukemia (AML-M2). Hematopoietic cells
of myeloid cells. Leukemic cells from most human AMLsfrom leukemic Faslpr/lprhMRP8bcl-2 animals form clo-
have been found to express Bcl-2 at levels much highernogenic blast colonies in vitro and can transfer disease
than their normal cellular counterparts (Delia et al., 1992;to wild-type mice. In vitro ligation of Fas on Fas1/1
Bensi et al., 1995), suggesting that deregulation of thehMRP8bcl-2 marrow cells depletes approximately 50%
bcl-2 gene may be one of the critical events in the my-of myeloid progenitor activity, demonstrating that Bcl-2
eloid transformation process. The extension of cellularcan only partially block Fas-mediated death signals in
survival by Bcl-2 may allow sufficient time for the acqui-myelomonocytic progenitors. In addition, Faslpr/lpr mar-
sition of additional oncogenic mutations. This mecha-row contains greatly increased numbers of myeloid
nism may underly the progression from chronic to acutecolony-forming cells as compared to Fas1/1 controls.
leukemia (Rabbitts, 1991, 1994).Taken together, these data suggest that Fas has a
To test directly the role of bcl-2 in the developmentnovel role in the regulation of myelopoiesis and that
of myeloid leukemia, we have created a transgenicFas may act as a tumor suppressor to control leuke-
mouse inwhich constitutive expression of thebcl-2 genemogenic transformation in myeloid progenitor cells.
is targeted exclusively to myeloid cells by the hMRP8
promoter (Lagasse and Weissman, 1994). hMRP8bcl-2
Introduction mice develop a disease that in many ways is analogous
to human chronic myelomonocytic leukemia (CMML)
Acute myeloid leukemia (AML) accounts for over 80% (Lagasse and Weissman, submitted). hMRP8bcl-2 trans-
of all adult acute leukemias (Schiffer, 1997) and is char- genic animals develop monocytosis with age and be-
acterized by a clonal expansion of immature myeloid come neutropenic due to a shift in granulopoiesis toward
cells in all hematopoietic tissues. Many patients pro- immature cell types. Whereas monocytes from wild-type
gress to AML from preleukemic myelodysplastic syn- mice rapidly undergo apoptosis invitro, monocytes from
dromes (MDS) or from chronic myelogenous leukemia hMRP8bcl-2 mice are able to survive in the absence of
(CML). This progression to blast crisis is thought to result serum or exogenous growth factors. We have recently
from the accumulation of genetic lesions in a single found that monocytes from patients with CMML similarly
self-renewing progenitor cell that prevents the normal have extended survival in vitro while monocytes from
maturation of the mutant cell and its progeny (reviewed healthy volunteers rapidly undergo apoptosis, suggesting
in Sawyers et al., 1991). that a disorder in programmed cell death of monocytes
Acute myeloblastic leukemia with maturation, or AML- is a critical feature of CMML (Lagasse and Weissman,
M2 as classified by the French-American-British (FAB) submitted). hMRP8bcl-2 mice show decreased survival
system (Bennett et al., 1976), is the most common sub- compared to their littermate controls but rarely develop
type of AML and is characterized by an accumulation of acute malignancies (Lagasse and Weissman, submit-
granulocyte precursors in all hematolymphoid tissues. ted). Despite the deregulation of Bcl-2 expression found
Surveys aimed at identifying molecular abnormalities in in many human cancers, overexpression of Bcl-2 alone
AML-M2 have found that approximately 40% of AML- has been found to be relatively benign in terms of cellular
M2 patients possess a t(8;21) chromosomal transloca- transformation in transgenic mouse models (Cory et al.,
tion that juxtaposes the aml1 and eto genes (Miyoshi et 1994). However, deregulated expression of Bcl-2 cou-
al., 1991). Aml1 is a transcription factor of the core bind- pled to additional mutations such as enforced expres-
ing factor (CBF) family and has been shown to up-regu- sion of c-Myc can rapidly lead to the transformation of
late the expression of several growth factor genes in- cells of the B lymphoid lineage (Vaux et al., 1988). We
cluding m-csf, gm-csf, and il-3 (reviewed in Tenen et thus reasoned that additional mutations are likely to
al., 1997), and is necessary for the formation of all hema- act in concert with bcl-2 deregulation to promote acute
topoietic lineages (Okuda et al., 1996; Wang et al., 1996). myeloid leukemia.
Loss-of-function mutations in the Fas receptor (CD95)
or in components of the Fas signaling pathway have*To whom correspondence should be addressed (e-mail: dtraver@
leland.stanford.edu). been implicated in several human AMLs (Robertson et
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Figure 1. Morphology of Leukemia in Faslpr/lpr hMRP8bcl-2 Mice
(A±C) Preparations of marrow (A), spleen (B), and blood (C) cells of leukemic mice compared to controls. Note predominance of myeloblasts
in all hematopoietic tissues in leukemic Faslpr/lpr hMRP8bcl-2 mouse (May-GruÈ nwald/Giemsa, all photos 3187.5 original magnification).
(D) Expression of human Bcl-2 in splenocytes. Expression is seen in all myeloid cells, including intermediate staining in leukemic blasts (3125
original magnification).
(E) Staining for NCAE in control (left) versus leukemic (right) splenocytes. Tumor cells stain slightly positive (red) for the granulocytic NCAE
marker (3125 original magnification).
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al., 1995; Bouscary et al., 1997). Despite this, nocompel- observation period of approximately 7 months. Of the
9 leukemic Faslpr/lpr hMRP8bcl-2 mice, 7 became mori-ling association between loss of Fas function and sub-
type of AML has been found. Granulocytes and their bund by 3±8 weeks of age and the other 2 at 4 and 7
months. Marrow in leukemic animals was hypercellularmyeloblastic progenitors are known to express high lev-
els of Fas (Liles et al., 1996), and several patients with and was largely composed of immature granulocytic
cells, of which myeloblasts predominated (Figure 1A;AML-M2 have been shown to have myeloblasts with
functional deficiencies in the Fas signaling pathway Table 1). Extramedullary hematopoiesis and prolifera-
tion of leukemic cells occurred in the spleen (Figure(Robertson et al., 1995; Dirks et al., 1997). In light of
these clinical findings, we bred Fas-deficient Faslpr/lpr 1B; Table 1), leading to splenomegaly in leukemic mice.
Greater than 30% of peripheral blood mononuclear cellsmice to hMRP8bcl-2 transgenic animals to determine
whether these two mutations that block programmed in leukemic animals were myeloblasts (Figure 1C; Table
1). Invasion of leukemic cells into the liver, kidneys, andcell death can cooperate to generate malignant myeloid
disease. lungs was also observed (data not shown). Leukemic
blasts were Mac-1int, Gr-1int, c-Kithi and negative forHere, we present an in vivo model of murine acute
myeloblastic leukemia in Fas-deficient animals constitu- lymphoid and erythroid markers by flow cytometry, con-
firming their myeloid origin (data not shown). Leukemictively expressing Bcl-2 in myeloid cells. Approximately
15% of Faslpr/lpr hMRP8bcl-2 mice reproducibly develop cells expressed moderate to high levels of human Bcl-2
(Figure 1D) and stained positively for napthol AS-D chlo-disease similar to human AML-M2, suggesting that de-
regulated expression of Bcl-2 and loss of Fas function roacetate esterase (NCAE) (Figure 1E), a diagnostic
marker of acute myeloblastic leukemia in humans. Leu-may be crucial events in the transformation of myelo-
blasts in both mouse and human. These results demon- kemic myeloblasts were immature in appearance with
open chromatin structure and few granules (Figuresstrate a previously unknown role for Fas in protecting
myeloid precursors from leukemogenic transformation. 1A±1C and 1G). Histochemical stains for monocytic and
In addition, predisposition to AML in Faslpr/lpr hMRP8bcl-2 lymphocytic markers were uniformly negative in leuke-
mice but not in Faslpr/lpr or hMRP8bcl-2 mice alone sug- mic blast cells (data not shown).
gests that Fas and Bcl-2 regulate distinct pathways of In summary, leukemic Faslpr/lpr hMRP8bcl-2 mice had
programmed cell death in the myeloid lineage. Finally, an expansion of myeloblasts in all hematopoetic tissues.
because not all mice bearing these mutations develop Leukemic myeloblasts appeared partially able to give
AML, it is likely that other oncogenic events are involved rise to more mature granulocytic elements, but the sub-
in the progression to acute myeloblastic leukemia. stantially lowered numbers of granulocytes in the mar-
row and blood of leukemic animals suggests that granu-
Results locytic maturation is impaired (Table 1). This phenotype
is remarkably similar to human AML-M2, or acute myelo-Generation of Faslpr/lpr hMRP8bcl-2 Mice
blastic leukemia with maturation, which is characterizedhMRP8bcl-2 mice overexpressing human Bcl-2 under
by .30% myeloblasts, .10% maturing granulocytic ele-the control of the human MRP8 promoter were gener-
ments, and ,20% monocytic cells in the nonerythroidated as previously described (Lagasse and Weissman,
marrow compartment (NEC). Averages from six leuke-1994). All transgenic animals used in this study were
mic Fas lpr/lpr hMRP8bcl-2mice showed 29% myeloblasts,derived from the high-expressing hMRP8bcl-2/2 founder.
46% maturing granulocytes, and 15% monocytic cellsTransgenic animals were crossed with B6.MRL-Faslpr/lpr
in the NEC (Table 1). A diagnostic hallmark of AML-M2mice. Resulting F1 Faslpr/1 animals were bled and screened
is the presence of stacked granule components knownfor human Bcl-2 expression by flow cytometry. The sta-
as Auer rods in the cytoplasm of leukemic myeloblasts.tus of the fas gene in F2 animals was determined by
We have never observed Auer rods in the blast cells ofPCR analysis (see Experimental Procedures for details).
any leukemic Fas lpr/lpr hMRP8bcl-2 mice. To our knowl-No deviations from expected genotype percentages
edge, Auer rods have yet to be described in any murinewere observed.
myeloid leukemia, possibly reflecting a difference be-
tween species. It is also possible, due to the apparentFaslpr/lpr hMRP8bcl-2 Mice Are Predisposed
immaturity of leukemic myeloblasts inFaslpr/lpr hMRP8bcl-2to Acute Myeloid Leukemia
mice (Figure 1G), that maturation arrest occurs ata stagehMRP8bcl-2 mice progressively develop monocytosis
in myeloblastic differentiation before sufficient granuleand associated neutropenia that leads to decreased
components have been synthesized.survival compared to littermate controls after 1 year of
No AML was observed in Faslpr/1 hMRP8bcl-2 animalsage (Lagasse and Weissman, submitted). Despite this
or in Faslpr/lpr animals crossed to the independently-CMML-like disease, hMRP8bcl-2 mice very rarely de-
derived hMRP8bcl-2/1 transgenic founderline, in whichvelop AML. We have also not observed any myeloid
the level of Bcl-2 expression is substantially lower andperturbations in Faslpr/lpr mice. When these two geno-
difficult to detect in myeloid progenitor cells (data nottypes were crossed,however, 9 of 60 Faslpr/lpr hMRP8bcl-2
mice developed acute myeloblastic leukemia over an shown). Faslpr/lpr hMRP8bcl-2 mice that did not develop
(F±G) Electron photomicrographs of splenocytes from a leukemic Fas lpr/lpr hMRP8bcl-2 mouse. Field view (F) shows myeloblasts (closed arrows)
and lymphocytes (open arrows). Note immaturity of myeloblast in closeup (G) as evidenced by the paucity of granules and open chromatin
structure (Field view 33000, blast closeup 37100 original magnification).
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Table 1. Hematological Parameters of Leukemia in Faslpr/lpr hMRP8bcl-2 Mice
Percentage of Cellsa
Promyelocyte Promonocyte Nucleated
Tissue Genotype n Blast Myelocyte Metamyelocyte Granulocyte Monocyte Lymphocyte Erythrocyte
Marrow Fas1/1 6 1.4 6 0.8 5.2 6 2.5 4.5 6 1.5 40.4 6 6.1 7.6 6 2.4 21.4 6 4.8 19.4 6 3.7
Faslpr/lpr 6 1.9 6 1.4 5.0 6 1.7 5.5 6 1.4 41.1 6 4.9 6.5 6 3.1 19.2 6 3.5 20.7 6 9.1
hMRP8bcl-2 9 4.7 6 4.4 7.6 6 3.0 9.2 6 2.3 21.5 6 10.3 20.0 6 3.1 17.9 6 4.9 19.2 6 5.9
Faslpr/lpr hMRP8bcl-2 6 3.3 6 2.0 6.3 6 1.2 12.7 6 7.0 31.0 6 6.8 22.9 6 7.8 13.1 6 4.0 10.7 6 6.3
leukemic Faslpr/lpr hMRP8bcl-2 6 21.7 6 9.5 17.2 6 7.3 11.1 6 7.1 6.1 6 3.4 10.9 6 6.2 7.3 6 4.4 25.7 6 3.1
Spleen Fas1/1 6 ,1 ,1 ,1 3.3 6 1.3 4.6 6 2.8 89.7 6 2.8 2.4 6 1.2
Faslpr/lpr 6 ,1 ,1 ,1 6.4 6 1.9 7.2 6 1.8 83.0 6 3.0 2.5 6 1.1
hMRP8bcl-2 7 2.2 6 1.9 2.7 6 1.9 4.2 6 2.8 7.2 6 4.9 11.7 6 4.7 58.7 6 15.3 13.2 6 10.2
Faslpr/lpr hMRP8bcl-2 6 1.8 6 1.8 4.4 6 1.1 5.8 6 3.4 8.1 6 4.4 14.6 6 4.6 48.3 6 9.2 17.0 6 4.0
leukemic Faslpr/lpr hMRP8bcl-2 6 15.9 6 7.4 9.8 6 2.8 7.5 6 5.0 2.3 6 1.4 23.1 6 14.4 24.7 6 13.3 16.7 6 14.3
Blood Fas1/1 6 ,1 ,1 ,1 11.4 6 4.2 6.1 6 2.1 81.0 6 7.2 ,1
Faslpr/lpr 5 ,1 ,1 1.7 6 1.3 19.5 6 5.3 3.9 6 3.1 74.9 6 6.3 ,1
hMRP8bcl-2 9 ,1 ,1 1.0 6 1.1 7.4 6 4.6 16.0 6 7.8 72.1 6 10.2 3.1 6 3.1
Faslpr/lpr hMRP8bcl-2 3 ,1 ,1 1.0 6 .02 13.9 6 4.2 35.4 6 16.0 49.0 6 13.0 ,1
leukemic Faslpr/lpr hMRP8bcl-2 6 34.9 6 23.0 9.0 6 7.1 2.1 6 2.2 7.1 6 5.8 15.6 6 9.0 28.7 6 22.2 2.7 6 2.5
a Differential cell counts were performed by identifying at least 300 cells per marrow and spleen cytospin and 100 cells per blood smear.
Numbers are presented as means plus or minus standard deviations.
AML displayed differential cell counts similar to those weeks following transplantation. The majority of mar-
row, spleen, and blood cells in leukemic recipient ani-from transgenic hMRP8bcl-2 animals (Table 1).
mals were immature myeloid elements, with a prepon-
derance of myeloblasts (Figure 2D). FACS analysis of theLeukemic Blasts Are Cytokine-Dependent and Form
hematopoietic systems of leukemic recipients showedClonogenic Blast Colonies In Vitro
cells to be exclusively derived from leukemic CD45.21The inability of blast cells to differentiate into more ma-
donor animals (Figure 2E, insets) and that nearly all cellsture cells is a hallmark of acute leukemia. To assess
were myeloid (Figure 2E). Cell cycle analyses showedthe differentiation capacity of blast cells from leukemic
transplanted cells to berapidly cycling, with 29.0 6 2.2%Fas lpr/lpr hMRP8bcl-2 mice, we transferred limiting num-
(n 5 3) of marrow and 44.5 6 9.0% (n 5 3) of spleenbers of splenocytes into methylcellulose cultures. As
cells in S/G2/M phase. Analysis of nonleukemic Fas lpr/lprwith most human myeloid leukemias, blast cells were
hMRP8bcl-2 mice showed 13.76 1.3% (n 5 6) of marrowunable to proliferate in culture without the addition of
and 14.9 6 3.7% (n 5 6) of spleen cells in S/G2/M phase.exogenous growth factors (Collins, 1987; Akashi et al.,
Both of the transplanted leukemias also transferred le-1991) (Figure 2A). In the presence of individual myeloid
thal disease to secondary recipients (data not shown).growth factors such as IL-3, GM-CSF, and G-CSF, how-
Thus, the transplantability of disease suggests that leu-ever, leukemic blasts rapidly gave rise to clonogenic
kemic cells are sufficiently transformed to be inherentlycolonies (Figure 2A). Of the cytokines tested, IL-3 and
leukemogenic.GM-CSF exhibited a synergistic effect on colony forma-
tion. Cultures with both IL-3 and GM-CSF gave rise to
251 6 10 colonies/5 3 104 cells, while cultures in GM- Fas-Deficient Marrow Contains Increased
CSF or IL-3 alone produced 179 6 12 or 21 6 5 colonies, Myeloid Progenitor Potential
respectively. Colonies displayed tightly grouped clus- We next sought to determine whether Fas-deficient he-
ters of cells indicative of leukemic blast cell colonies matopoietic progenitors possess intrinsic defects that
(Akashi et al., 1991) (Figure 2B), and morphological ex- might predispose Faslpr/lpr animals toward leukemia. To
amination showed individual colonies to be composed assess changes in the multipotent hematopoietic stem
entirely of immature myeloblasts (Figure 2C). cell (HSC) compartment, we compared the frequencies
of Thy-1.1loSca-11c-Kithilin-/lo cells, which are highly en-
riched for HSC activity, between all mouse genotypesAcute Myeloid Leukemia Can Be Transplanted
to Recipient Animals used in this study by flow cytometry according to pre-
viously published techniques (Spangrude et al., 1988;To test further the transformation of cells from leukemic
Fas lpr/lpr hMRP8bcl-2 mice, mixtures of 5 3 106 marrow Morrison and Weissman, 1994). While hMRP8bcl-2 ani-
mals displayed significantly increased percentages ofcells and 1 3 107 splenocytes were injected into lethally
irradiated or nonirradiated wild-type recipient animals HSCs compared to wild-type animals, no significant dif-
ferences were observed in HSC frequency between(see Experimental Procedures for details). Only recipient
animals whose hematolymphoid systems had been ab- hMRP8bcl-2 and Faslpr/lpr hMRP8bcl-2 mice (data not
shown). To test primitive multipotent progenitors func-lated by lethal irradiation supported donor-derived leu-
kemic cells. Cells from two of six leukemic Faslpr/lpr tionally, we performed spleen colony-forming unit assays
(CFU-S) with marrow donor cells from all genotypeshMRP8bcl-2 mice used as donors transferred disease,
and recipients developed fatal blast crises at 3 and 15 used in this study. Day 12 CFU-S activity is correlated
Blockade of Myeloid Cell Death Leads to AML
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Figure 2. Transformation Assays
(A) Colony production from leukemic Fas lpr/lpr
hMRP8bcl-2 splenocytes in methylcellulose
supplemented with growth factors. Numbers
of colonies presented are per 5 3 104 input
cells.
(B) Clonogenic day 3 colony from culture con-
taining IL-3/GM-CSF. Note tight grouping of
cells and homogeneity of cell size indicative
of leukemic blast colonies.
(C) Morphology of cells from colony in (B).
All cells retain the myeloblastic morphology
observed in the leukemic donor mouse (May-
GruÈnwald/Giemsa staining).
(D) Morphology of marrow, spleen, and blood
cells from a C57BL/Ka-Thy1.1, CD45.1 re-
cipient mouse that developed AML 3 weeks
following transplantation from a leukemic
Faslpr/lpr hMRP8bcl-2 donor animal (3187.5
original magnification).
(E) FACS analysis of hematopoietic tissues of
the leukemic recipient in (D). Almost all cells
are myeloid in marrow, spleen, and blood and
are exclusively derived from the leukemic
Faslpr/lpr hMRP8bcl-2 (CD45.2) donor animal
(insets). Shaded histograms represent CD45.2
profiles from a C57BL/Ka-Thy1.1, CD45.1 ani-
mal that did not receive transplanted cells.
with long-term and transient multipotent progenitor cell also showed a 5-fold increase in myeloid progenitor
activity (Figure 3B). Morphological examination of colo-frequencies (Till and McCulloch, 1961; Wu et al., 1967).
Marrow cells (1 3 105) were injected into lethally irradi- nies derived from each donor genotype showed most
cells to be undifferentiated myeloid blasts and showedated syngeneic recipients, and spleen colonies were
counted on day 12. Only modest increases in colony no significant differences among remaining cell types
(data not shown).numbers were seen in animals receiving marrow cells
from Faslpr/lpr, hMRP8bcl-2, and Faslpr/lpr hMRP8bcl-2 Both day 12 and day 8 CFU-S assays using 1 3 106
donor spleen cells showed increased colony numbersmice compared to wild-type marrow (Figure 3A). Thus,
no significant increases in HSC frequency or in day 12 only in recipients injected with hMRP8bcl-21 spleno-
cytes (Figures 3A and 3B, respectively). This is due toCFU-S multipotent progenitor activity were seen in Fas-
deficient mice. increased numbers of progenitors in the spleen that
results from extramedullary hematopoiesis occurring inTo compare functional differences in myeloerythroid
progenitor activity, we performed day 8 CFU-S experi- these animals (Lagasse and Weissman, submitted).
ments using 1 3 105 input marrow cells (Becker et al.,
1963; Wu et al., 1967). In contrast to the day 12 CFU-S Blastic Myeloid Cells Express High Levels of Fas
The above results suggest that signaling through theresults, Fas lpr/lpr mice displayed large differences in day
8 colony numbers compared to controls (Figure 3B). Fas receptor negatively regulates myelopoiesis by con-
trolling homeostasis of myeloid progenitor populations.Whereas hMRP8bcl-2 marrow produced an approxi-
mate 2-fold increase in colony numbers, Fas lpr/lpr marrow We thus predicted that Fas expression would be high
on myeloid progenitor cells in the marrow of wild-typecontained a 5-fold increase in myeloid progenitor activ-
ity (Figure 3B). Marrow from Faslpr/lpr hMRP8bcl-2 mice mice. Marrow cells were divided by flow cytometry into
Immunity
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Figure 3. CFU-S Assays
(A) Colony numbers from spleens harvested
12 days after injection of limiting numbers of
marrow or spleen cells. Numbers are pre-
sented as colonies/1 3 106 input cells.
(B) Colony numbers from spleensharvested on
day 8. Note increased numbers of colonies
derived from the marrow of Fas-deficient
mice. Heterogeneity in splenic colony num-
bers from hMRP8bcl-2 transgenics is due to
variable extramedullary hematopoiesis oc-
curring in these mice.
three populationsÐlow, intermediate, and highÐbased similar up-regulation, we plated marrow cells in media
containing GM-CSFand IL-3, potent stimulatorsof gran-on expression of the Fas receptor (Figure 4A). Increasing
levels of Fas correlated with increasing levels of the ulopoiesis (Metcalf, 1989). Compared to cultures con-
taining serum alone, Fas levels rose significantly on my-myeloid activation marker Mac-1 (Figure 4B). Scatter
profiles of marrow myeloid cells were then obtained by eloid cells in cultures supplemented with GM-CSF/IL-3
over 2 days (Figures 5A and 5B, respectively). Myeloidgating on cells positive for both Mac-1 and Gr-1 (Figure
4C). Blastic myeloid cells (72%) were found to express cells from hMRP8bcl-2 marrow showed an especially
large increase in Fas expression (Figure 5B). We cannothigh levels of Fas (Figure 4C). Cells sorted from this
population displayed the morphology of immature my- rule out the possibility, however, that selective survival
of subpopulations of cells may account for the increasedeloid cells (data not shown).
numbers of cells with higher Fas expression.
Fas Expression Is Up-Regulated by Myeloid
Growth Factors Myeloid Progenitors Are Susceptible
to Fas-Mediated KillingFas is known to be up-regulated on lymphoid cells upon
antigen receptor triggering and/or upon stimulation by That myeloid progenitor cells express high levels of Fas
(Figure 4C) and that myeloid activation is coupled to Fasactivating cytokines (Daniel and Krammer, 1994; Alder-
son et al., 1995). To determine if myeloid cells exhibit up-regulation (Figure 5B) suggests that the Fas receptor
Figure 4. Myeloid Blasts Express High Levels of Fas
(A) Histogram showing Fas expression on marrow cells from a Fas1/1 mouse. Cells were gated based on Fas expression for further analysis
in (B). Cells within the Faslo, Fasint, and Fashi gates represent 36%, 42%, and 22% of the total population, respectively. Lighter histogram
represents Fas staining on marrow cells from a Faslpr/lpr mouse.
(B) Myeloid markers were analyzed on populations of marrow cells subdivided by Fas expression levels. Myeloid cells with the highest levels
of Mac-1/Gr-1 expression were found in the Fashi fraction.
(C) Myeloid cells were gated from total marrow cells based on expression of Mac-1/Gr-1 markers from (B) (boxes) and analyzed for scatter
characteristics. Marrow cells from the Fashi compartment contained the majority of blastic myeloid cells.
Blockade of Myeloid Cell Death Leads to AML
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Figure 5. Up-Regulation of Fas by Growth
Factors
(A) Marrow cells from Faslpr/lpr, Fas1/1, and
hMRP8bcl-2 mice were cultured for 2 days in
media containing 10% FCS. Cells were sub-
sequently removed, washed, stained for Fas,
and analyzed by flow cytometry. Gr-11 cells
are displayed in histograms. Mean fluores-
cence intensities for Faslpr/lpr, Fas1/1, and
hMRP8bcl-2 plots are 25.2, 44.5, and 67.6,
respectively.
(B) Marrow cells were cultured as in (A) with
the addition of GM-CSF and IL-3. Cytokine
stimulation up-regulated Fas expression on
myeloid cells; the largest increase occurred
in cells from hMRP8bcl-2 mice. Mean fluores-
cence intensities are 23.5, 55.5, and 91.9 for
Faslpr/lpr, Fas1/1, and hMRP8bcl-2 plots, re-
spectively.
may functionally regulate myelopoiesis. To test this di- least partially nonoverlapping, pathways of programmed
cell death in myeloid progenitors. This is in agreementrectly, we performed Fas-killing assays on marrow my-
eloid cells. Marrow cells were harvested from control, with previous evidence showing that overexpression of
Bcl-2 in FDC-P1 murine myeloid leukemia cells couldhMRP8bcl-2, Fas lpr/lpr, and Faslpr/lpr hMRP8bcl-2 mice and
activated in vitro for 2 days with GM-CSF and IL-3. The only partially block Fas-mediated killing signals (Itoh et
al., 1993). Likewise, Fas and Bcl-2 apparently regulateFas receptor was then ligated on these cells by antibody
cross-linking; cells were subsequently plated in methyl- independent apoptotic pathways in cellsof the lymphoid
system (Strasser et al., 1995).cellulose containing myeloid growth factors (see Experi-
mental Procedures for details). Following Fas ligation, The remarkable conservation in disease phenotype
among numerous leukemic Faslpr/lpr hMRP8bcl-2 animalscolony counts dropped approximately 5-fold from wild-
type marrow and 2-fold from hMRP8bcl-2 marrow, com- suggests that myeloblasts are prone to transformation
by this combination of mutations. That this murine leuke-pared to respective marrow samples without antibody
(Table 2). Marrow cells from Fas-deficient animals treated mia so closely resembles human AML-M2 also suggests
that the molecular bases for these diseases may bewith anti-Fas antibody showed nosignificant differences
in colony numbers (Table 2). conserved. Several clinical studies support our finding
in this mouse model that blockade of the cell death
pathways normally regulated by Bcl-2 and Fas may leadDiscussion
to AML-M2. Leukemic blasts from patients with AML-
M2 have been shown to express high levels of Bcl-2In this study, we have generated Fas-deficient mice with
constitutive expression of Bcl-2 targeted specifically to relative to normal blasts from healthy volunteers (Delia
et al., 1992; Bensi et al., 1995). Additional studies havemyeloid cells by the hMRP8 promoter. The fact that
many Faslpr/lpr hMRP8bcl-2 mice develop AML provides provided evidence that blast cells from several subtypes
of AML, including AML-M2, often express decreasednovel evidence that Fas not only plays a role in myelo-
poietic homeostasis but also that Fas can act as a tumor levels of Fas receptor protein on their surface compared
to normal cellular counterparts (Komada et al., 1995;suppressor to control leukemogenic transformation in
granulocyte progenitors. The development of AML in Robertson et al., 1995). Also, leukemic blasts expressing
Fas are often unable to respond to stimulation of theFaslpr/lpr hMRP8bcl-2 animals, but not in either single-
mutant genotype, shows that gain-of-function bcl-2 mu- Fas receptor in vitro (Dirks et al., 1997), suggesting that
aberrant signaling elements downstream of the Fas re-tations collaborate synergistically with loss-of-function
Fas mutations in the transformation of primitive myeloid ceptor may functionally mimic the absence of the Fas
receptor in our model.cells. We further show that constitutive expression of
Bcl-2 only partially blocks Fas-mediated death signals, The t(8;21) chromosomal translocation that creates
the AML1/ETO fusion protein in myeloid progenitors issuggesting that Fas and Bcl-2 regulate distinct, or at
Table 2. Myeloid Progenitor Assay
Genotype
Fas1/1 Faslpr/lpr hMRP8bcl-2 Faslpr/lpr hMRP8bcl-2
No Ab 30 6 3 82 6 3 50 6 3 35 6 4
1Anti-Fas Ab 6 6 2a 73 6 6b 24 6 6a 40 6 6b
Fas receptor cross-linking was performed on marrow cells activated for 2 days in culture. 105 marrow cells were then plated in triplicate in
methylcellulose containing GM-CSF/IL-3. Colonies were counted at day 6 and are presented as means plus or minus standard deviations.
Representative experiment of three shown.
a p , 0.05.
b No significant difference.
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currently the best known molecular anomaly associated have low remission rates following inductive chemother-
apeutic regimens (Min et al., 1996). Taken together,with AML-M2 (Miyoshi et al., 1991; Erickson et al., 1992).
Patients in long-term remission following treatment for these clinical data support our finding that the loss of
Fas function is important in the etiology of acute myeloidt(8;21)1 AML-M2 have been found to maintain produc-
tion of the AML1/ETO fusion protein in myeloerythroid leukemia. Mutations in Fas signaling pathways may also
provide a mechanism by which leukemic cells avoidprogenitor cells (Nucifora et al., 1993; Miyamoto et al.,
1996). Thissuggests that t(8;21)1 progenitors require addi- immune surveillance and resist cytoreductive therapies.
tional genetic lesions for transformation. Similarly, in-
complete incidence of disease in Faslpr/lpr hMRP8bcl-2
Role of Fas in Granulopoiesismice suggests that somatic mutations are necessary
Transformation of the earliest defined granulocytic pro-for leukemogenesis. It is thus possible that a similar
genitor in Faslpr/lpr hMRP8bcl-2 mice prompted us totranslocation or deregulation of the aml1 or eto genes
question the role of the Fas receptor in normal granulo-may collaborate with mutagenesis of the apoptosis
poiesis. As AML is often associated with derangedpathways regulated by Fas and Bcl-2 to lead to murine
multipotent progenitor cells, we first sought to deter-AML-M2. Karyotypic analyses of leukemic cells from
mine whether lack of the Fas receptor might perturbFas lpr/lpr hMRP8bcl-2 mice revealed no gross chromo-
this population in the marrow of Fas lpr/lpr mice. Previoussomal abnormalities (data not shown). Since detection
research in our laboratory has shown that Fas is notof subtle abnormalities in murine chromosomes is diffi-
expressed in HSCs (Aguila and Weissman, 1996). Ac-cult, we are currently searching for alterations in the
cordingly, HSC frequency did not significantly differ be-aml1 and eto genes in leukemic blasts from Faslpr/lpr
tween Faslpr/lpr mice and Fas1/1 mice (data not shown).hMRP8bcl-2 mice.
Day 12 CFU-S colony numbers also showed no signifi-
cant differences between these two genotypes. These
data suggest that the Fas receptor does not play anFas as a Tumor Suppressor
Oncogenesis is kept in check by tumor suppressor pro- important role in regulating hematopoiesis by primitive,
multipotent progenitor cells.teins that induce apoptosis in aberrant cells (reviewed
in Marshall, 1991; Weinberg, 1991). The results pre- We next assessed the role of Fas in granulocyte pro-
genitors. In vivo, day 8 CFU-S colony production showedsented in this study suggest that the Fas receptor pos-
sesses a tumor suppressor function in myeloid progeni- dramatic increases from Faslpr/lpr marrow over Fas1/1
marrow, suggesting that Fas normally limits the prolifer-tor cells. hMRP8bcl-2 mice very rarely develop acute
myeloid malignancies; when both alleles of the fas gene ative potential of myeloerythroid progenitors. In vitro,
we show that Fas is expressed on blastic granulocyteare inactivated, however, these transgenic animals have
a greatly increased incidence of AML. progenitor cells, is up-regulated on myeloid cells cul-
tured with IL-3 and GM-CSF, and can functionally de-Trimerization of the Fas receptor transmits potent
death signals in most hematopoietic cells (reviewed in plete myeloid progenitor activity upon receptor cross-
linking. No significant decrease in myeloid progenitorNagata, 1997) and induces apoptosis in activated T lym-
phocytes in a process known as activation-induced cell activity was observed when fresh, uncultured marrow
was used in similar experiments. That substantial deple-death (AICD) (Singer and Abbas, 1994; Alderson et al.,
1995). The accumulation of large numbers of T cells in tion of myeloid progenitor activity requires prior activa-
tion by cytokines suggests that signaling through theFas lpr/lpr mice presumably results from the inability of
previously activated peripheral T cells to be cleared (Rus- Fas receptor may regulate homeostasis in proliferating
myeloid progenitors by limiting average cellular lifespan.sell et al., 1993). Despite this buildup of cells that pheno-
typically resembles a preleukemic condition, Faslpr/lpr A model of homeostatic control of myeloid progeni-
tors through the Fas receptor requires the presencemice are not prone to develop T cell leukemia. Evidence
that Fas may have a tumor suppressor function in B of Fas ligand±bearing cells. Cytotoxic T lymphocytes
(CTLs) express high levels of FasL and can efficientlycells, however, was revealed in T cell±deficient Faslpr/lpr
mice (Peng et al., 1996). Over 70% of Faslpr/lpr mice lack- kill Fas-bearing cells (Kagi et al., 1994; Lowin et al., 1994;
Suda and Nagata, 1994). CTLs are rare in bone marrow,ing T cells developed lethal B cell lymphoma, while T
cell±intact Faslpr/lpr mice showed only background inci- however, and studies in T cell-deficient Faslpr/lpr mice
have shown no significant alteration in myelopoiesis ordence. T cell±deficient Fas1/1 animals (10%) developed
B lymphoma. These data suggest that T cell surveillance myeloid leukemogenesis. Recent work has shown that
neutrophils express high levels of FasL (Liles et al.,normally controls B cell transformation through Fas-
independent mechanisms and that stimulation of Fas by 1996), suggesting that granulopoiesis may be partially
regulated by a negative feedback mechanism throughnon±T cells prevents the majority of B cell lymphomas.
A recent clinical study in patients with myelodysplas- interactions between progeny and progenitor.
Faslpr/lpr mice display normal steady-state granulo-tic syndromes has shown that myeloid progenitor cells
often lose expression of the Fas receptor upon progres- poiesis and show no obvious accumulation of myeloid
progenitors, suggesting that additional mechanisms ex-sion to AML (Bouscary et al., 1997). This observation
was supported functionally by the finding that cells from ist to eliminate superfluous cells in the myeloid lineage.
Differences in myeloid progenitor activity are apparent,MDS patients in transition to more advanced disease
become increasingly resistant to Fas-mediated killing however, inspleen colony-forming assays where limiting
numbers of Fas-deficient marrow cells produce severalin vitro. Studies in patients with AML have shown that
individuals with blast cells expressing low levels of Fas times the number of colonies from wild-type marrow
Blockade of Myeloid Cell Death Leads to AML
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AS-D choloracetate esterase was performed according to manufac-cells. This may suggest that expansion of myeloid col-
turer's instructions (Sigma Diagnostics). Antibody staining for hu-ony-forming cells is normally regulated through Fas re-
man Bcl-2 was done as previously described (Lagasse and Weiss-ceptor/Fas ligand interactions in a manner similar to the
man, 1997).
process of AICD that limits the expansion of activated
lymphoid populations. The greatest expansion of the
Cell Culturemyeloid population takes place during the initiation of
Marrow cells were harvested, counted, and plated in RPMI medium
myelopoiesis in embryonic development. The fact that containing 10% fetal calf serum (FCS; Gibco BRL), 50 U/ml rmGM-
leukemic Faslpr/lpr hMRP8bcl-2 mice become consis- CSF (Genzyme), and 200 U/ml rmIL-3 (Genzyme). A fraction of cells
were removed after 36±48 hr and analyzed for Fas expression bytently moribund approximately 5±10weeks following the
flow cytometry. Remaining cells were split and processed for Fas-initiation of myelopoiesis in utero suggests that trans-
killing assays. All cultures were maintained at 378C in incubatorsforming events may occur during the early amplification
containing 7% CO2.of the myeloid lineage. It is likely, since hMRP8bcl-2
animals rarely develop acute malignancies, that immune
Clonogenic Progenitor Assayssurveillance targets aberrant cells through the Fas re-
Splenocytes (1 3 105) from leukemic Faslpr/lpr hMRP8bcl-2 mice were
ceptor/Fas ligand system and controls similar preleuke- plated in alpha-Modified Eagle Medium±based methylcellulose me-
mic or leukemic clones from expanding in transgenic or dia (Methocult M3100; Stem Cell Technologies) that was supple-
wild-type animals. mented with 30% FCS, 1% bovine serum albumin, 2 mM L-gluta-
mine, and 50 mM 2-mercaptoethanol. The following cytokines, aloneThe results presented in this study have elucidated a
or in combination, were added at the beginning of culture: rhM-CSFrole for the Fas receptor in the complex process of
(25 U/ml; Genzyme), rhG-CSF (100 ng/ml; Genzyme), rmGM-CSFhomeostasis in myeloid progenitor cells. Although other
(10 ng/ml), rmIL-3 (30 ng/ml), and rmSlf (100 ng/ml; Immunex Corpo-
genes are clearly involved in the regulation of granulo- ration). Colonies were counted on day 3. All cultures were maintained
poiesis, signaling through theFas receptor can eliminate at 378C/7% CO2 in humidified chambers.
activated myeloid progenitors, which may serve to keep For Fas-killing assays, marrow cells were incubated on ice with
Jo-2 (hamster anti-mouse Fas mAb; 50 mg/ml; low endotoxin/nothe great proliferative potential of these cells in check.
sodium azide; Pharmingen) for 45 min. Cells were washed in PBS,Significant predisposition to acute myeloblastic leuke-
centrifuged, and resuspended in media containing biotinylated anti-mia in Faslpr/lpr hMRP8bcl-2 mice suggests that Fas and
hamster IgG antibody for 30 min followed by streptavidin (10 mg/
Bcl-2 regulate distinct pathways of programmed cell ml) for 20 min. Cells were washed, counted, and plated in triplicate
death in myeloid progenitors. The fact that not all Faslpr/lpr in Methocult M3100 supplemented as above and containing rmGM-
hMRP8bcl-2 mice develop AML indicates that at least one CSF (10 ng/ml) and rmIL-3 (30 ng/ml). Colonies were counted on
day 6.more oncogenic event is required in primitive myeloid
cells or their progenitors for the progression to acute
myeloblastic leukemia. The striking similarity of this mu- Cell Transfers
Mixtures of 5 3 106 marrow cells and 1 3 107 splenocytes fromrine disease to human AML-M2 suggests that similar
leukemic animals (C57BL/Ka-Thy1.1, CD45.2) were injected into thedefects may underlie transformation of myeloblasts in
retroorbital sinusoids of congenic recipient animals (C57BL/Ka-both mouse and human and provides a model in which
Thy1.1, CD45.1) having previously received either 920 rad in a split
to study further oncogenic alterations leading toward dose or no irradiation. Recipient mice were 8 to 14 weeks of age at
AML. the time of transplantation. Marrow cells (2 3 105) from C57BL/
Ka-Thy1.1, CD45.1 mice were added to ensure radioprotection of
Experimental Procedures recipient animals. Mice were monitored twice a week for sickness
and sacrificed when moribund.
Mice
Faslpr/lpr hMRP8bcl-2 animals were generated by breeding hMRP8bcl-2
Flow Cytometry
transgenic mice (C57Bl/Ka-Thy1.1) (Lagasse and Weissman, 1994)
Single-cell suspensions were prepared from hematopoietic tissues
to B6.MRL-Faslpr/lpr mice obtained from the Jackson Laboratory (Bar
and stained for FACS analyses using the following monoclonal anti-Harbor, ME). Faslpr/lpr hMRP8bcl-2 animals were then bred with
bodies (mAbs): M1/70 (anti-Mac-1); 8C5 (anti-Gr-1); ALI-4A2 (anti-B6.MRL-Faslpr/lpr animals. Offspring were screened as outlined be-
CD45.1); A20.1 (anti-CD45.2); 2B8 (anti-c-Kit); and Jo-2 (anti-Fas).low. All genotypes presented were backcrossed onto the C57Bl/
All antibodies except Jo-2 (Pharmingen) were prepared in our labo-Ka-Thy1.1 background (referred to in the text as Fas1/1) for at least
ratory and directly conjugated to phycoerythrin, fluorescein-isothio-three generations to minimize strain differences. All hMRP8bcl-2
cyanate, allophycocyanin, or biotin. Biotinylated MAbs were de-animals presented in this study are from the hMRP8bcl-2/2 high-
tected with streptavidin coupled to Texas red (Cappel). Nonspecificexpressing founderline. Mice presented in this study were generally
binding of MAbs was prevented by preincubation with 2.4G2, anbetween 3±10 weeks of age. Faslpr/lpr hMRP8bcl-2 mice showed no
MAb which blocks high-affinity Fc receptor subtypes. Viable cellssigns of AML unless noted as leukemic. All animals were maintained
gated by light scatter and exclusion of propidium iodide (0.5 mg/ml)in Stanford University's Research Animal Facility in accordance with
were analyzed on a FACS Vantage (Becton Dickinson). Cell cycle
Stanford guidelines.
analyses were performed as previously described (Fleming et al.,
1993). Data analyses were performed using software developed by
Screening
the Stanford University Shared FACS Facility.
Faslpr/lpr hMRP8bcl-2 mice were screened for human Bcl-2 expres-
sion by flow cytometry as previously described (Lagasse and Weiss-
man, 1994). Screening for the Faslpr mutant allele was carried out CFU-S Assays
Recipient C57BL/Ka mice having previously received a split doseby a PCR protocol published previously (Singer and Abbas, 1994).
of 920 rad were retroorbitally injected with 1 3 105 marrow or 1 3
106 spleen cells from control, Faslpr/lpr, hMRP8bcl-2, orhealthy Fas lpr/lprHistological and Immunohistological Methods
Cells (2 3 105) from marrow or spleen suspensions were cytocentri- hMRP8bcl-2 mice. Five wild-type recipient animals were used per
donor mouse; three donors were used per genotype. Recipientsfuged onto glass slides according to the manufacturer's instructions
(Shandon). Cellular morphology was assessed following staining in were sacrificed at 8 or 12 days postinjection. Spleen colonies were
visualized and counted as described (Till and McCulloch, 1961).May-GruÈ nwald and Giemsa solutions (Fluka). Staining for napthol
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